• 29 April 2016

    Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently in a Phase II clinical study in Wilson Disease patients.

  • 30 March 2016

    Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that it has recruited the first patient  into a Phase I monotherapy trial of its lead programme, IMCgp100, for the treatment of uveal melanoma.

  • 28 March 2016

    Sonendo announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next generation of it’s GentleWave® System. This clearance provides the endodontist with the choice of using the default treatment cycles or reducing the treatment cycles as desired based on their evaluation of a tooth for root canal treatment using the GentleWave System. This most recent FDA clearance is in alignment with Sonendo’s commitment to develop products that improve clinical efficacy, treatment efficiency, and practice economy for the endodontist. Randy W. Garland, DDS, Garland Endodontics, Encinitas, CA, stated “The increase versatility of this upgrade gives the Endodontist control to treat the variety of clinical situations we are presented with.”

  • 17 March 2016

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, today announced positive Phase I study results for TOP1288, its lead compound for the treatment of ulcerative colitis (UC). TopiVert will present the Phase I study data at the 11th Congress of ECCO in Amsterdam on Friday 18 March 2016. 

  • 9 March 2016

    Funding will support further Clinical Evaluation and Market Access for 4Tech TriCinch™, a breakthrough technology for Transcatheter Valve Repair (TTVR).